Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor

Title:Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor

Volume: 31

Author(s): Yu Jiang, Yingnan Wu, Jing Wang, Yuheng Ma, Hui Yu and Zhanli Wang*

Affiliation:

• Inner Mongolia Key Laboratory of Disease-Related Biomarkers, The Second Affiliated Hospital, Baotou Medical College, Baotou, China

Keywords: SARS-CoV-2, Main protease, Inhibitor, Fragment-based drug discovery

Abstract: Severe Acute Respiratory Syndrome Coronavirus Type 2 (SARS-CoV-2) emerged at the end of 2019, causing a highly infectious and pathogenic disease known as 2019 coronavirus disease. This disease poses a serious threat to human health and public safety. The SARS-CoV-2 main protease (Mpro) is a highly sought-after target for developing drugs against COVID-19 due to its exceptional specificity. Its crystal structure has been extensively documented. Numerous strategies have been employed in the investigation of Mpro inhibitors. This paper is primarily concerned with Fragment-based Drug Discovery (FBDD), which has emerged as an effective approach to drug design in recent times. Here, we summarize the research on the approach of FBDD and its application in developing inhibitors for SARS-CoV-2 Mpro.

Cite this article as:

Jiang Yu, Wu Yingnan, Wang Jing, Ma Yuheng, Yu Hui and Wang Zhanli*, Fragment-based Drug Discovery Strategy and its Application to the Design of SARS-CoV-2 Main Protease Inhibitor, Current Medicinal Chemistry 2024; 31 () . https://dx.doi.org/10.2174/0109298673294251240229070740